Schroder Investment Management Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Schroder Investment Management Group’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,305	Closed	-$393K	–	1361
2018 Q2	$393K	Hold	25,305	–	–	﹤0.01%	1079
2018 Q1	$435K	Hold	25,305	–	–	﹤0.01%	1073
2017 Q4	$555K	Hold	25,305	–	–	﹤0.01%	1082
2017 Q3	$988K	Buy	+25,305	New	+$794K	﹤0.01%	978
2017 Q1	–	Sell	-15,198	Closed	-$762K	–	1283
2016 Q4	$762K	Hold	15,198	–	–	﹤0.01%	944
2016 Q3	$798K	Hold	15,198	–	–	﹤0.01%	938
2016 Q2	$628K	Buy	+15,198	New	+$661K	﹤0.01%	953

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Schroder Investment Management Group's FPRX Position: Q3 2018 in Review

Schroder Investment Management Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2018, closing a stake of 25,305 shares — an estimated $393K sold.

Schroder Investment Management Group first reported a position in FPRX in Q2 2016 and held it in 7 quarters. The position peaked at $988K in Q3 2017. 114 funds tracked by Wall St. Rank hold FPRX as of Q3 2018.

Schroder Investment Management Group reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Schroder Investment Management Group sold 25,305 Five Prime Therapeutics, Inc. shares in Q3 2018, an estimated $393K.
Schroder Investment Management Group first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
Schroder Investment Management Group's Five Prime Therapeutics, Inc. position peaked at $988K in Q3 2017.
114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2018.

Based on Schroder Investment Management Group's 13F filing for Q3 2018, filed 13 Nov 2018.